Want to see IN:ORTINGLOBE full AI Analyst Report?
ORTINGLOBE Stock Chart & Stats
₹11.55
₹0.54(3.15%)
At close: 4:00 PM EST
₹11.55
₹0.54(3.15%)
Day’s Range― - ―
52-Week Range₹11.18 - ₹21.15
Previous CloseN/A
Volume283.00
Average Volume (3M)1.02K
Market Cap
₹121.97M
Enterprise Value₹119.05
Total Cash (Recent Filing)₹6.06M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding8,131,392
10 Day Avg. Volume1,277
30 Day Avg. Volume1,025
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)9.31
Price to Sales (P/S)114.55
P/FCF Ratio-20.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FY2026 Revenue GrowthThe sharp FY2026 revenue increase indicates that the company achieved meaningful top-line expansion over the prior year. If management can stabilize margins and control costs, this larger revenue base could support improved operating leverage and provide a foundation for future recovery.
Positive Shareholders’ EquityPositive equity in both reported years provides a capital buffer against losses and liabilities, even though that cushion has weakened. Maintaining positive net worth gives the company more financial resilience than an already balance-sheet-insolvent position while it works to improve operations.
Improved Free Cash FlowThe move in free cash flow from negative to break-even represents an improvement in cash investment and funding needs over the prior year. Although operating cash flow remains weak, reduced free-cash-flow consumption could help preserve liquidity if the improvement becomes sustainable.
Bears Say
Severe Profitability CollapseProfitability deterioration is severe, with gross profit turning negative and operating and net losses reaching very large levels relative to revenue. Such extreme margin pressure undermines the quality of reported growth, increases funding needs, and makes a near-term earnings recovery dependent on major cost and business-model improvements.
Persistent Negative Operating Cash FlowNegative operating cash flow in both reported years shows that the core business is consuming cash rather than funding its own operations. This weakens cash-generation quality, may require external financing to sustain activity, and limits the company’s ability to invest or absorb further operating setbacks.
Materially Higher LeverageThe sharp increase in debt relative to equity reduces financial flexibility while the company is experiencing substantial losses. A heavier debt burden can raise refinancing and solvency risk, increase pressure on future cash flows, and constrain capital allocation until operating performance improves.
Ortin Global Ltd News
ORTINGLOBE FAQ
What was Ortin Global Ltd’s price range in the past 12 months?
Ortin Global Ltd lowest stock price was ₹11.18 and its highest was ₹21.15 in the past 12 months.
What is Ortin Global Ltd’s market cap?
Ortin Global Ltd’s market cap is ₹121.97M.
When is Ortin Global Ltd’s upcoming earnings report date?
Ortin Global Ltd’s upcoming earnings report date is Nov 18, 2026 which is in 51 days.
How were Ortin Global Ltd’s earnings last quarter?
Ortin Global Ltd released its earnings results on Aug 14, 2026. The company reported -₹0.416 earnings per share for the quarter.
Is Ortin Global Ltd overvalued?
According to Wall Street analysts Ortin Global Ltd’s price is currently Overvalued.
Does Ortin Global Ltd pay dividends?
Ortin Global Ltd does not currently pay dividends.
What is Ortin Global Ltd’s EPS estimate?
Ortin Global Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ortin Global Ltd have?
Ortin Global Ltd has 8,131,392 shares outstanding.
What happened to Ortin Global Ltd’s price movement after its last earnings report?
Ortin Global Ltd reported an EPS of -₹0.416 in its last earnings report. Following the earnings report the stock price went down -2.675%.
Which hedge fund is a major shareholder of Ortin Global Ltd?
Currently, no hedge funds are holding shares in IN:ORTINGLOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ortin Global Ltd
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories Limited until its name change in June 2024, offers an extensive portfolio of pharmaceutical formulations available as tablets, capsules, syrups, and dry powders. These products address a wide spectrum of therapeutic areas, including anti-diabetics, anti-allergics, cardiovascular conditions, sedatives, anti-helminthics, analgesics, antipyretics, various antibiotics (quinolones, penicillins, cephalosporins, macrolides), antifungals, chemotherapeutics, antacids, anti-ulcerants, anti-spasmodics, calcium and iron supplements, anti-arthritic drugs, protein supplements, enzymes, vitamins, as well as psychiatry, appetite stimulant, gynecological, and anti-retroviral medications. Beyond finished dosage forms, Ortin Global produces active pharmaceutical ingredient (API) intermediates for anti-retroviral, anti-diabetic, analgesic, antipyretic, antibiotic, antifungal, anti-ulcerant, and anti-malarial applications. Its manufacturing capabilities also extend to fine chemicals, Grignard products, and alkali metal compounds. The company provides a range of specialized services, including process development, characterization of processes and products, analytical research and development, and assay development. It also offers R&D for new formulation brands and diagnostic services, focusing on the creation of rapid flow kits, assays, and reagents. Additionally, Ortin Global secures long-term contracts for manufacturing intermediates and developing new APIs, functions as a merchant exporter of finished pharmaceutical formulations, and holds interests in real estate.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―